CANbridge Pharmaceuticals receives registration approval for NERLYNX®
Category: #health  By Saipriya Iyer  Date: 2019-11-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

CANbridge Pharmaceuticals receives registration approval for NERLYNX®

Puma Biotechnology, Inc. has reportedly announced that its licensing partner CANbridge Pharmaceuticals Inc., based in Greater China, has secured registration approval to market NERLYNX® (neratinib) from the Department of Health in Hong Kong.  The drug has been developed for extended adjuvant therapy of adult patients with early stage hormone receptor positive HER2 amplified and overexpressed breast cancer. The drug can also be administered to patients who have  undergone adjuvant trastuzumab-based treatment less than a year ago.

James Xue, PhD, Founder, CEO and Chairman, CANbridge Pharmaceuticals, reportedly stated that seamless approval of NERLYNX through Hong Kong regulatory procedure  for market approval is an indication  of the company’s regulatory proficiency, and its commitment to bring novel therapies to underserved patient populations in greater China. NERLYNX is the first targeted treatment to be approved in CANbridge’s oncology platform, which will allow the company to facilitate offer a latest and essential treatment to females in Hong Kong, with HER2-positive breast cancer at possibility of recurrence,  as  soon as it is  approved in the West, he further added.

Alan H. Auerbach, Chief Executive Officer, Chairman, and President, Puma Biotechnology,was apparently noted saying that the registration approval through partnership with CANbridge represents an important opportunity  for the company to pursue its globalization targets . The partner company has the commercial infrastructure and resources to provide NERLYNX to patients across the region, he further added.

 About 20%-25% of breast cancer tumors over-express the HER2 protein. This cancer is often more critical than other forms of breast cancer, which augments the risk of development of disease and death. While research has revealed that trastuzumab can lessen the risk of early stage HER2-positive breast cancer, it has been noted that up to 25% of patients treated with trastuzumab are at a risk of experiencing recurrence of the disease.
 

Source article:

https://investor.pumabiotechnology.com/press-release/puma-biotechnology-licensing-partner-canbridge-pharmaceuticals-receives-registration-a



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Elevon set to buy Sage Pay to enhance its reach to global customers
Elevon set to buy Sage Pay to enhance its reach to global customers
By Saipriya Iyer

As the world is progressing towards digitalization, the e-commerce is gaining widespread traction across the globe. Keeping the progress of e-commerce alive, various companies worldwide are investing into the M&As....

Triple Gene releases Phase 1 study data for INXN-4001 in heart failure
Triple Gene releases Phase 1 study data for INXN-4001 in heart failure
By Saipriya Iyer

Triple Gene LLC- a U.S. based cardiovascular gene therapy enterprise recently furnished preliminary data from its Phase 1 trial of INXN-4001, an investigational therapeutic candidate used in the treatment of cardiac fa...

Alibaba plans to offer bitcoin rewards to shoppers through Lolli
Alibaba plans to offer bitcoin rewards to shoppers through Lolli
By Saipriya Iyer

 

  • Now Alibaba shoppers can earn free bitcoin when they purchase products on Alibaba's e-commerce platform
  • Reportedly, the partnership would enable shoppers...